Publications

Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups. by Castanheira M, Farrell SE, Krause KM, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2014; 58 (2): 833-838

Activity of Echinocandins and Triazoles Against a Contemporary (2012) Worldwide Collection of Yeast and Moulds Collected from Invasive Infections, Lead author: Castanheira M/Pfaller M, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftaroline Activity Tested against Bacterial Isolates from Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation (AWARE) Program for the United States (2011-2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Emerging Resistant Serotype 19A Streptococcus pneumoniae in Adults in the US, Lead author: Isturiz RE, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Role of an Older Tetracycline for Treatment of Multidrug-resistant Acinetobacter spp. Infections: Understanding the Enhanced Potency of Minocycline!, Lead author: Jones RN, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested Against Pseudomonas aeruginosa Isolates from United States Medical Centers (2011-2012), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Activity of Ceftazidime-Avibactam Tested Against Enterobacteriaceae Isolates with Characterized &#223-Lactamase Encoding Genes Collected from United States Hospitals During 2012, Lead author: Castanheira M, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftolozane/tazobactam Activity Tested against Aerobic Gram-negative Organisms Isolated from Intraabdominal Infections in European and United States Hospitals (2012), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Frequency of Occurrence and Antimicrobial Susceptibility of Gram-negative Organisms Isolated from Healthcare Associated Urinary Tract Infections: Results from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftazidime-avibactam Activity Tested Against Contemporary (2012) Gram-negative Organisms Causing Bloodstream Infections in United States (USA) Medical Centers, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Activity of Ceftazidime-Avibactam Tested Against Contemporary (2012) Pathogens from Urinary Tract and Intraabdominal Infections from Patients in the USA, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2012: Regional Activity of Linezolid and Comparator Compounds, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Evaluation of Daptomycin Activity Tested against 164,457 Bacterial Strains from Hospitalized Patients: Summary of 8 Years of Surveillance Program Worldwide (2005-2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Bacterial Isolates from Patients with Bacteremia in United States Medical Centers (2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Contemporary (2012) Bacteria Isolated from Community-Acquired Respiratory Tract Infections, Including Oxacillin-resistant S. aureus, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Multidrug Resistant (MDR) Streptococcus pneumoniae in the USA (2009-2012), Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Serotype distribution of Streptococcus pneumoniae recovered principally from non-sterile sites in patients aged =18 years in the US (2009-2011), Lead author: Hollingsworth RC, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Streptococcus pneumoniae serotype 3 recovered predominantly from non-sterile sites in patients aged =18 years in the USA (2009-2011), Lead author: Hewlett D, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Post Beta-Lactamase Inhibitor Effect of Tazobactam when Associated with Ceftolozane and Tested against ESBL-Producing Strains, Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Relationship between Ceftolozane/Tazobactam Exposure and E. coli Resistance Amplification Prevention in a Hollow Fiber Infection Model, Lead author: VanScoy, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Identification of a Translational Relationship Between Tazobactam Exposure in Combination with Ceftolozane and Efficacy against ESBL-Producing Enterobacteriaceae, Lead author: Ambrose PG, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

PK/PD of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model, Lead author: Nicasio, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Report of Linezolid Activity from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2012 (Europe, Latin America, Asia Pacific, Canada), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Oritavancin activity against S. aureus Causing Invasive Infections in USA and European Hospitals: A Five-year International Surveillance Program, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Oritavancin Tested against Uncommonly Isolated Gram-positive Pathogens Responsible for Documented Infections in Hospitals Worldwide, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftaroline Tested against 10,956 Organisms Causing Acute Bacterial Skin and Skin Structure Infections in United States Medical Centers (2012), Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam Tested against Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Gram-negative Pathogens from the Europe-Mediterranean Region, China and USA, Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftazidime-avibactam Tested against Contemporary (2012) Gram-negative Organisms Collected from United States Medical Centers, Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftazidime-avibactam and Comparator Agents Tested against Urinary Tract Isolates from a Global Surveillance Program (2011), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam and Comparator Agents Tested against Isolates from Europe-Mediterranean Region Surveillance (2011), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftolozane/tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States and European Hospitals (2012), Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftaroline-avibactam Tested against Contemporary (2012) Isolates Collected from United States Hospitals with Well Characterized &#223-lactamases, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam Tested against Contemporary Pathogens from Hospitalized Pneumonia Patients in the USA (2012), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of the Fluoroquinolone JNJ-Q2 Tested against Contemporary (2012) Pathogens Isolated from the Global SENTRY Surveillance Platform, Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

S. pneumoniae Serotype Distribution and Antimicrobial Susceptibility Prior to and Post USA Introduction of 13-valent Pneumococcal Conjugate Vaccine, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftriaxone Non-susceptibility in Emerging (35B) and Persisting (19A, 19F) S. pneumoniae Serotypes in the USA (2011 – 2012): Only Ceftaroline Retains Activity among &#223-lactams, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Genotypic Characterization of Methicillin-resistant Staphylococcus aureus Strains Recovered from Pneumonia Clinical Trials for Ceftobiprole, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Interim use of Vancomycin Susceptibility Testing Results to Predict Activity of Oritavancin, a New Long Acting Lipoglycopeptide, Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Re-evaluating the Contemporary (2007-2011) Spectrums of Tetracyclines (Minocycline, Doxycycline, and Tetracycline) Tested against Enterobacteriaceae and Acinetobacter spp., Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity Of The Novel Pleuromutilin BC-3781 Tested against Bacterial Pathogens Causing Sexually Transmitted Diseases, Lead author: Paukner, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity Activity of Cadazolid against Gram-positive Clinical Isolates, Including Linezolid-resistant Subsets with Defined Resistance Mechanisms, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of ß-lactam Agents Tested in Combination with Novel &#223-lactamase Inhibitor Compounds against Enterobacteriaceae Producing Extended-spectrum ß-lactamases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

ß-lactam Activity Tested in Combination with β-lactamase Inhibitor Candidates against Enterobacteriaceae Producing Class A, B and D Carbapenemases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity of AZD0914: A New Benzisoxazole DNA Gyrase Inhibitor against Neisseria gonorrhoeae, Lead author: Huband, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of the First-in-class Lpxc Inhibitor ACHN-975 and Comparators Tested against Gram-negative Organisms Including Isolates with Characterized Resistance Mechanisms, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Comparison of EUCAST and CLSI Broth Microdilution Methods for the Susceptibility Testing of 10 Systemically Active Antifungal Agents against Candida spp., Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Intra- and Interlaboratory Study of Antifungal Susceptibility Testing of Isavuconazole against Aspergillus Strains, Lead author: Ghannoum, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Detection of fks Gene Hot Spot Mutations in Candida glabrata by CLSI Broth Microdilution Testing of Anidulafungin, Caspofungin and Micafungin using Epidemiological Cutoff Values, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Use of Micafungin as a Surrogate Marker to Predict Susceptibility and Resistance to Caspofungin among 3,747 Clinical Isolates of Candida using CLSI Methods and Interpretive Criteria, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Isavuconazole and Comparator Antifungals Tested against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO